The California Supreme Court gave final clearance Wednesday to California's landmark $3-billion stem cell research effort, declining to hear an appeal of two lower court rulings upholding the constitutionality of 2004's Proposition 71.
"This is the end of the road," said Dana Cody, executive director of the Life Legal Defense Foundation, which represents two of the taxpayer and religious groups that sued.
Experts agreed that the plaintiffs had exhausted legal challenges, at least as far as the funding is concerned.
"Although some might think the U.S. Supreme Court could have a majority of justices unsympathetic to embryonic stem cell research, there is no plausible federal law claim in their case for the Supreme Court to hear," said Hank Greely, a Stanford University law professor who specializes in health law and bioscience.
The state is expected to issue the first of $3 billion in voter-approved bonds by July. The lawsuit did not prevent the state from issuing the bonds, but in practice the cloud it cast made a sale unfeasible until now.
"At this point, they could file challenges against some action we take as a board," said Robert Klein, author of Proposition 71 and chairman of the state stem cell institute oversight committee. "But what's critical to understand is they can't stop the research. The future for the next decade is assured for California and for medical research."
Though deprived of bond funding, the voter-created California Institute for Regenerative Medicine has not stood still for the last two years. Cobbling together a $150-million state loan arranged by Gov. Arnold Schwarzenegger and $50 million in loans from California philanthropists, the institute has awarded $158 million in grants, making California the world's leading funder of human embryonic stem cell research, experts say.
"We're ahead of everybody else, and we'll stay ahead of everybody else," Greely said.
The state and private loans had been made with the understanding that if the institute did not prevail in the lawsuits, they would not be repaid. Klein said proceeds from the first bonds issued will go to repayment.
The bonds will provide up to $350 million a year for 10 years. By comparison, the U.S. government spends about $30 million a year on human embryonic stem cell research and restricts grants to just a handful of human embryonic stem cell lines.
